Experienced in Chronic B-Cell Leukemia (CBCL)

Lei H. Nie

Union Hospital, 
Wuhan, CN 
Experienced in Chronic B-Cell Leukemia (CBCL)
Union Hospital, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Lei Nie practices in Wuhan, China. Ms. Nie is rated as an Experienced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Gallbladder Cancer, Tissue Biopsy, and Gastrostomy.

Her clinical research consists of co-authoring 409 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Female

Locations

Union Hospital, Wuhan, 430022, China
Other Locations
100 Kexue Avenue, Zhengzhou, 450001, China
No. 348 Dexiang Street, Jiamusi, 154002, China
220 Handan Road, Shanghai, 200433, China
107 Wenhua W Road, Jinan, 250012, China
N0. 44 West Wenhua Road, Jinan, 250012, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3

409 Total Publications

Hydroxyproline-Modified Chitosan-Based Hydrogel Dressing Incorporated with Epigallocatechin-3-Gallate Promotes Wound Healing Through Immunomodulation.
Hydroxyproline-Modified Chitosan-Based Hydrogel Dressing Incorporated with Epigallocatechin-3-Gallate Promotes Wound Healing Through Immunomodulation.
Journal: Gels (Basel, Switzerland)
Published: August 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Nie's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile